Healthcare Industry News: Head and Neck Cancer
News Release - May 2, 2011
TomoHD(TM) Radiation Therapy System Selected by UCSF Medical CenterPremier Hospital to Become First Using TomoTherapy(R) Technology in San Francisco
MADISON, WI--(Healthcare Sales & Marketing Network) - TomoTherapy Incorporated (NASDAQ:TOMO ), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that University of California, San Francisco (UCSF) Medical Center has purchased a TomoTherapy® TomoHD™ treatment system. Upon installation later this year, UCSF Medical Center will become the first treatment center using the TomoTherapy treatment platform in San Francisco. UCSF Medical Center ranks among the nation's top 10 premier hospitals according to U.S. News & World Report's 2010-11 America's Best Hospitals survey.
"At UCSF, we are on a mission to provide the optimal treatment for every cancer case we treat," said Dr. Mack Roach, professor, Radiation Oncology and Urology at UCSF. "Our state-of-the-art arsenal of radiation therapy solutions helps us ensure that our patients have access to the very best, and most appropriate, treatment available anywhere in the world."
The TomoHD system enables clinicians to accurately and efficiently treat tumors throughout the body with advanced image-guided, intensity-modulated radiation therapy (IG-IMRT) capabilities. The system's integrated imaging and treatment delivery capabilities provide an improved workflow for treating large field tumors, as well as prostate and Head and Neck Cancers, among others.
"We are very pleased to offer cutting-edge radiation therapy solutions to patients," said Fred Robertson, M.D., TomoTherapy's president and CEO. "Adoption of the TomoHD treatment system provides clinicians with a flexible and efficient option for delivering high quality treatments to a wide range of tumors."
About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its Hi-Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
The information stated above was prepared by TomoTherapy and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of TomoTherapy, or any of its products, by The Regents of the University of California, its officers, agents and employees.
©2011 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi-Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.